



Stewardship of Antibiotics for Multidrug-Resistant Gram-Negative Bacteria

Guest Editors:

Dr. Daniele Roberto Giacobbe

Department of Health Sciences
(DISSAL), Università degli Studi di
Genova, 16132 Genoa, Italy

Dr. Ilias Karaiskos

Department of Internal Medicine
– Infectious Diseases, Hygeia
Hospital, Athens, Greece

Deadline for manuscript
submissions:

closed (30 November 2019)

Message from the Guest Editors

Dear Colleagues,

In the last decades, multidrug-resistant Gram-negative bacteria (MDR-GNB) have represented an important threat.

Recently, some much awaited novel agents have become available, restoring our ability to effectively counteract some perilous infections due to these organisms. However, it remains imperative to administer novel agents thoughtfully and in line with antimicrobial stewardship principles, in order to: (i) delay the development of resistance to novel agents; (ii) delay the diffusion of resistance to novel agents.

The present special issue focuses on stewardship of both old and novel antibiotics for MDR-GNB infections. We especially encourage submission of original articles and reviews. However, case reports describing peculiar stewardship situations and decisions in patients with MDR-GNB infections will also be considered.

Keywords: antimicrobial resistance; MDR; antimicrobial stewardship; multidrug-resistant Gram-negative bacteria; Acinetobacter; Pseudomonas; Klebsiella; KPC; OXA; NDM; IMP; VIM; ESBL

Dr. Daniele Roberto Giacobbe

Dr. Ilias Karaiskos

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPUS / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1
(*General Pharmacology, Toxicology and Pharmaceutics*)

Contact Us

Antibiotics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)